Nickolas Papadopoulos
Gründer bei Thrive Earlier Detection Corp.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Christoph S. Lengauer | M | 59 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 5 Jahre |
Dan Edelstein | M | - |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | - |
Isaac Ro | M | 46 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA.
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | 3 Jahre |
Bert Vogelstein | M | - |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million.
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 5 Jahre |
Kenneth W. Kinzler | M | - |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million.
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 3 Jahre |
Isaac Kinde | M | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 5 Jahre |
Joshua Cohen | M | - |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | 3 Jahre |
Neil Exter | M | 65 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | - |
Sarah Larson | F | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 4 Jahre |
R. Jacob Vogelstein | M | - |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | - |
George C. Petrocheilos | M | 32 |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | - |
Mike Pellini | M | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | - |
Samantha Singer | F | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David Daly | M | 62 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 2 Jahre |
Steven Kafka | M | 54 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 2 Jahre |
Alexis Borisy | M | 52 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | - |
Dina Ciarimboli | F | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 3 Jahre |
Matthew Franklin | M | 50 |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 1 Jahre |
Nickolas Mark | M | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 1 Jahre |
Seema Bhan | F | - |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 20 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Nickolas Papadopoulos
- Persönliches Netzwerk